) reported second-quarter 2014 earnings (including stock-based
compensation expenses) of 80 cents per share, which surpassed the
Zacks Consensus Estimate by 3 cents. The company's earnings were 70
cents per share in the year-ago quarter. We note that figures have
been adjusted to reflect the two-for-one stock split effective last
month. Investors were not pleased with the narrow earnings beat
leading to a decline in the company's shares.
Quarter in Details
Total revenues climbed 17% year over year to $1.87 billion in the
second quarter. Revenues were boosted by the impressive performance
of Revlimid. Net product sales climbed 18% year over year to $1.84
billion. Revenues surpassed the Zacks Consensus Estimate of $1.85
Net sales of Revlimid, the key growth driver at Celgene, came in at
$1.2 billion, reflecting an increase of 15% over the year-ago
period. The drug did well both in the U.S. (up 15%) and
international markets (up 17%). Market share gains, geographic
expansion and increased duration of therapy drove sales in the
reported quarter. The drug is approved in many countries across the
globe in combination with dexamethasone for treating multiple
myeloma (MM) patients, who have received at least one prior
therapy. Revlimid is also approved in the U.S. in the relapsed
refractory mantle cell lymphoma indication.
Revlimid is also available in many countries for treating
transfusion-dependent anemia due to low or intermediate-1-risk
myelodysplastic syndrome (MDS) associated with a deletion 5q
cytogenetic abnormality (with or without additional cytogenetic
irregularities). Celgene is looking to expand the drug's label. To
attain the objective, it has filed regulatory applications in the
U.S. and EU in the newly diagnosed MM indication. The FDA target
date is Feb 22, 2015.
Net sales of another cancer drug, Abraxane, jumped 39% year over
year to $215 million. Net sales of Vidaza declined 28% year over
year to $152 million. Soft U.S. sales (down 89%) due to generic
competition hurt results during the quarter. U.S. sales of another
oncology drug Pomalyst came in at $104 million, up 16.8%
sequentially. The drug gained FDA approval in Feb 2013.
The approval of the drug (trade name: Imnovid) in the EU was gained
in Aug 2013. Sales of the drug in international markets were $57
million in the second quarter of 2014 compared to $47 million in
the preceding quarter.
All other product sales (inclusive of Thalomid, Istodax and an
authorized generic version of Vidaza in the U.S.) came in at $98
million in the second quarter, up 22.5%.
Research and development (R&D) expenses (excluding stock-based
compensation and other special items) increased 15.1% to $397
million. The increase was due to Celgene's efforts to develop its
pipeline. Selling, general and administrative (SG&A) expenses
(excluding stock-based compensation and other special items)
increased 14.6% to $440 million. Costs associated with the launch
of Otezla for psoriatic arthritis (FDA approval gained in Mar 2014)
and pre-launch activities related to the drug in the
moderate-to-severe psoriasis indication (U.S. target date: Sep 23,
2014) pushed up SG&A costs. Otezla sales were $5 million in the
Outlook for 2014 Upped
Celgene now expects total revenues to increase 17% year over year
to $7.6 billion (old guidance $7.5 billion) driven by strong
product sales. Net product sales are expected to grow 18% in 2014
to over $7.5 billion (old guidance: $7.3 billion to $7.4 billion).
Revlimid is expected to be the major contributor with sales
expected at approximately $4.95 billion (old guidance: $4.9 billion
to $5.0 billion), up 16%. Abraxane net sales are projected in the
range of $850 million to $900 million. Celgene expects earnings
(excluding stock-based compensation and other special items) in the
range of $3.60 to $3.65 per share (old guidance: $3.50 to $3.60),
Celgene carries a Zacks Rank #2 (Buy). Better-ranked stocks in the
healthcare sector include Salix Pharmaceuticals Ltd. (
), Biogen Idec (
) and Allergan (
). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
To read this article on Zacks.com click here.